MDBiologix

MDBiologix is a clinical-stage biotechnology company focused on the discovery and development of next-generation multi-specific antibody therapeutics for oncology and immunology. The company utilizes its proprietary MDB (Multi-specific Drug Building) platform to engineer biologics that can simultaneously modulate multiple immune pathways. Its lead candidate, MDB-101, is a PD-L1/IL-15 fusion protein currently in Phase 1 clinical trials for the treatment of advanced solid tumors. MDBiologix maintains research and development operations in both Suzhou, China, and South San Francisco, USA, to leverage global talent and resources. The company is backed by prominent life science investors and aims to provide innovative solutions for patients with refractory cancers.